Ex Vivo Virotherapy with Myxoma Virus to Treat Cancer

Nancy Villa, Lina S. Franco, Douglas McFadden

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Myxoma virus (MYXV) is a member of the Poxviridae family and the genus Leporipoxvirus. In nature MYXV tropism is restricted to lagomorphs, and is specifically pathogenic only for European rabbits (Oryctolagus cuniculus), in which this virus causes the lethal systemic disease called myxomatosis. Importantly, although MYXV cannot cause any disease pathology in humans, mice, or any other domestic animals other than rabbit, this virus can productively infect and kill a variety of human and murine cancer cells, from either primary sources or cultured cancer cell lines. Therefore, in the last decade, MYXV has emerged as a novel oncolytic virus against hematologic malignancies and various solid cancers. One novel aspect of MYXV virotherapy is a new systemic virus delivery strategy to cancer sites in the recipient, by which adsorption of the virus to isolated leukocytes is conducted prior to reinfusion of the virus-infected cells back into the recipient, via a procedure called ex vivo virotherapy (EVV, or simply EV2). The EV2 delivery strategy thus exploits the inherent migratory properties of leukocytes to ferry MYXV to tissue sites bearing cancer cells that are accessible to leukocyte chemotaxis. Here, we describe EV2 procedures with MYXV to systemically deliver the virus to sites of disseminated and/or metastatic cancer in situ via infected leukocytes derived from either bone marrow or peripheral blood.

Original languageEnglish (US)
Title of host publicationMethods in Molecular Biology
PublisherHumana Press Inc.
Pages95-110
Number of pages16
DOIs
StatePublished - Jan 1 2020

Publication series

NameMethods in Molecular Biology
Volume2058
ISSN (Print)1064-3745
ISSN (Electronic)1940-6029

Fingerprint

Myxoma virus
Viruses
Neoplasms
Leukocytes
Rabbits
Leporipoxvirus
Lagomorpha
Leukocyte Chemotaxis
Oncolytic Viruses
Poxviridae
Tropism
Domestic Animals
Hematologic Neoplasms
Adsorption
Cultured Cells
Bone Marrow
Pathology
Cell Line

Keywords

  • Bone marrow
  • Cancer cells
  • Flow cytometry
  • Myxoma virus
  • Peripheral mononuclear cells

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics

Cite this

Villa, N., Franco, L. S., & McFadden, D. (2020). Ex Vivo Virotherapy with Myxoma Virus to Treat Cancer. In Methods in Molecular Biology (pp. 95-110). (Methods in Molecular Biology; Vol. 2058). Humana Press Inc.. https://doi.org/10.1007/978-1-4939-9794-7_6

Ex Vivo Virotherapy with Myxoma Virus to Treat Cancer. / Villa, Nancy; Franco, Lina S.; McFadden, Douglas.

Methods in Molecular Biology. Humana Press Inc., 2020. p. 95-110 (Methods in Molecular Biology; Vol. 2058).

Research output: Chapter in Book/Report/Conference proceedingChapter

Villa, N, Franco, LS & McFadden, D 2020, Ex Vivo Virotherapy with Myxoma Virus to Treat Cancer. in Methods in Molecular Biology. Methods in Molecular Biology, vol. 2058, Humana Press Inc., pp. 95-110. https://doi.org/10.1007/978-1-4939-9794-7_6
Villa N, Franco LS, McFadden D. Ex Vivo Virotherapy with Myxoma Virus to Treat Cancer. In Methods in Molecular Biology. Humana Press Inc. 2020. p. 95-110. (Methods in Molecular Biology). https://doi.org/10.1007/978-1-4939-9794-7_6
Villa, Nancy ; Franco, Lina S. ; McFadden, Douglas. / Ex Vivo Virotherapy with Myxoma Virus to Treat Cancer. Methods in Molecular Biology. Humana Press Inc., 2020. pp. 95-110 (Methods in Molecular Biology).
@inbook{03b1775982d04c8596c27a1b0ab358ca,
title = "Ex Vivo Virotherapy with Myxoma Virus to Treat Cancer",
abstract = "Myxoma virus (MYXV) is a member of the Poxviridae family and the genus Leporipoxvirus. In nature MYXV tropism is restricted to lagomorphs, and is specifically pathogenic only for European rabbits (Oryctolagus cuniculus), in which this virus causes the lethal systemic disease called myxomatosis. Importantly, although MYXV cannot cause any disease pathology in humans, mice, or any other domestic animals other than rabbit, this virus can productively infect and kill a variety of human and murine cancer cells, from either primary sources or cultured cancer cell lines. Therefore, in the last decade, MYXV has emerged as a novel oncolytic virus against hematologic malignancies and various solid cancers. One novel aspect of MYXV virotherapy is a new systemic virus delivery strategy to cancer sites in the recipient, by which adsorption of the virus to isolated leukocytes is conducted prior to reinfusion of the virus-infected cells back into the recipient, via a procedure called ex vivo virotherapy (EVV, or simply EV2). The EV2 delivery strategy thus exploits the inherent migratory properties of leukocytes to ferry MYXV to tissue sites bearing cancer cells that are accessible to leukocyte chemotaxis. Here, we describe EV2 procedures with MYXV to systemically deliver the virus to sites of disseminated and/or metastatic cancer in situ via infected leukocytes derived from either bone marrow or peripheral blood.",
keywords = "Bone marrow, Cancer cells, Flow cytometry, Myxoma virus, Peripheral mononuclear cells",
author = "Nancy Villa and Franco, {Lina S.} and Douglas McFadden",
year = "2020",
month = "1",
day = "1",
doi = "10.1007/978-1-4939-9794-7_6",
language = "English (US)",
series = "Methods in Molecular Biology",
publisher = "Humana Press Inc.",
pages = "95--110",
booktitle = "Methods in Molecular Biology",

}

TY - CHAP

T1 - Ex Vivo Virotherapy with Myxoma Virus to Treat Cancer

AU - Villa, Nancy

AU - Franco, Lina S.

AU - McFadden, Douglas

PY - 2020/1/1

Y1 - 2020/1/1

N2 - Myxoma virus (MYXV) is a member of the Poxviridae family and the genus Leporipoxvirus. In nature MYXV tropism is restricted to lagomorphs, and is specifically pathogenic only for European rabbits (Oryctolagus cuniculus), in which this virus causes the lethal systemic disease called myxomatosis. Importantly, although MYXV cannot cause any disease pathology in humans, mice, or any other domestic animals other than rabbit, this virus can productively infect and kill a variety of human and murine cancer cells, from either primary sources or cultured cancer cell lines. Therefore, in the last decade, MYXV has emerged as a novel oncolytic virus against hematologic malignancies and various solid cancers. One novel aspect of MYXV virotherapy is a new systemic virus delivery strategy to cancer sites in the recipient, by which adsorption of the virus to isolated leukocytes is conducted prior to reinfusion of the virus-infected cells back into the recipient, via a procedure called ex vivo virotherapy (EVV, or simply EV2). The EV2 delivery strategy thus exploits the inherent migratory properties of leukocytes to ferry MYXV to tissue sites bearing cancer cells that are accessible to leukocyte chemotaxis. Here, we describe EV2 procedures with MYXV to systemically deliver the virus to sites of disseminated and/or metastatic cancer in situ via infected leukocytes derived from either bone marrow or peripheral blood.

AB - Myxoma virus (MYXV) is a member of the Poxviridae family and the genus Leporipoxvirus. In nature MYXV tropism is restricted to lagomorphs, and is specifically pathogenic only for European rabbits (Oryctolagus cuniculus), in which this virus causes the lethal systemic disease called myxomatosis. Importantly, although MYXV cannot cause any disease pathology in humans, mice, or any other domestic animals other than rabbit, this virus can productively infect and kill a variety of human and murine cancer cells, from either primary sources or cultured cancer cell lines. Therefore, in the last decade, MYXV has emerged as a novel oncolytic virus against hematologic malignancies and various solid cancers. One novel aspect of MYXV virotherapy is a new systemic virus delivery strategy to cancer sites in the recipient, by which adsorption of the virus to isolated leukocytes is conducted prior to reinfusion of the virus-infected cells back into the recipient, via a procedure called ex vivo virotherapy (EVV, or simply EV2). The EV2 delivery strategy thus exploits the inherent migratory properties of leukocytes to ferry MYXV to tissue sites bearing cancer cells that are accessible to leukocyte chemotaxis. Here, we describe EV2 procedures with MYXV to systemically deliver the virus to sites of disseminated and/or metastatic cancer in situ via infected leukocytes derived from either bone marrow or peripheral blood.

KW - Bone marrow

KW - Cancer cells

KW - Flow cytometry

KW - Myxoma virus

KW - Peripheral mononuclear cells

UR - http://www.scopus.com/inward/record.url?scp=85071758708&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071758708&partnerID=8YFLogxK

U2 - 10.1007/978-1-4939-9794-7_6

DO - 10.1007/978-1-4939-9794-7_6

M3 - Chapter

C2 - 31486033

AN - SCOPUS:85071758708

T3 - Methods in Molecular Biology

SP - 95

EP - 110

BT - Methods in Molecular Biology

PB - Humana Press Inc.

ER -